- Trade Name: Braftovi (Array Biopharma Inc)
- Indications: in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- Class: BRAF inhibitor, Kinase inhibitor
- Half-life: 3.5 hours
- FDA Approval Date: 06/27/2018
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
